{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T11:49:30Z","timestamp":1790682570555,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T00:00:00Z","timestamp":1690416000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00277-023-05359-3","type":"journal-article","created":{"date-parts":[[2023,7,27]],"date-time":"2023-07-27T19:02:06Z","timestamp":1690484526000},"page":"2845-2855","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Enhanced efficacy of combined fluzoparib and chidamide targeting in natural killer\/T-cell lymphoma"],"prefix":"10.1007","volume":"102","author":[{"given":"Chen","family":"Gong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiazhuo","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenting","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongwen","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cunzhen","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyang","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhuangzhuang","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhaoming","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3581-551X","authenticated-orcid":false,"given":"Mingzhi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,7,27]]},"reference":[{"key":"5359_CR1","doi-asserted-by":"publisher","first-page":"2460","DOI":"10.1038\/s41375-021-01313-2","volume":"35","author":"H Wang","year":"2021","unstructured":"Wang H, Fu BB, Gale RP, Liang Y (2021) NK-\/T-cell lymphomas. Leukemia 35:2460\u20132468","journal-title":"Leukemia"},{"key":"5359_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1186\/s13045-018-0559-7","volume":"11","author":"X Li","year":"2018","unstructured":"Li X, Cheng Y, Zhang M et al (2018) Activity of pembrolizumab in relapsed\/refractory NK\/T-cell lymphoma. J Hematol Oncol 11:15","journal-title":"J Hematol Oncol"},{"key":"5359_CR3","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1186\/s13045-022-01293-5","volume":"15","author":"E Tse","year":"2022","unstructured":"Tse E, Zhao WL, Xiong J, Kwong YL (2022) How we treat NK\/T-cell lymphomas. J Hematol Oncol 15:74","journal-title":"J Hematol Oncol"},{"key":"5359_CR4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.molcel.2010.06.017","volume":"39","author":"R Krishnakumar","year":"2010","unstructured":"Krishnakumar R, Kraus WL (2010) The PARP side of the nucleus: molecular actions, physiological outcomes, and clinical targets. Mol Cell 39:8\u201324","journal-title":"Mol Cell"},{"key":"5359_CR5","doi-asserted-by":"publisher","first-page":"5597","DOI":"10.1128\/MCB.02248-06","volume":"27","author":"AE Fisher","year":"2007","unstructured":"Fisher AE, Hochegger H, Takeda S, Caldecott KW (2007) Poly(ADP-ribose) polymerase 1 accelerates single-strand break repair in concert with poly(ADP-ribose) glycohydrolase. Mol Cell Biol 27:5597\u20135605","journal-title":"Mol Cell Biol"},{"key":"5359_CR6","first-page":"2546","volume":"45","author":"H Hanzlikova","year":"2017","unstructured":"Hanzlikova H, Gittens W, Krejcikova K, Zeng Z, Caldecott KW (2017) Overlapping roles for PARP1 and PARP2 in the recruitment of endogenous XRCC1 and PNKP into oxidized chromatin. Nucleic Acids Res 45:2546\u20132557","journal-title":"Nucleic Acids Res"},{"key":"5359_CR7","doi-asserted-by":"publisher","first-page":"239","DOI":"10.5114\/pjp.2015.54957","volume":"66","author":"A Kruk","year":"2015","unstructured":"Kruk A, Ociepa T, Urasi\u0144ski T, Grabarek J, Urasi\u0144ska E (2015) PARP-1 expression in CD34+ leukemic cells in childhood acute lymphoblastic leukemia: relation to response to initial therapy and other prognostic factors. Pol J Pathol 66:239\u2013245","journal-title":"Pol J Pathol"},{"key":"5359_CR8","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1007\/s11523-019-00680-2","volume":"14","author":"E Sachdev","year":"2019","unstructured":"Sachdev E, Tabatabai R, Roy V, Rimel BJ, Mita MM (2019) PARP inhibition in cancer: an update on clinical development. Target Oncol 14:657\u2013679","journal-title":"Target Oncol"},{"key":"5359_CR9","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.ccell.2019.07.007","volume":"36","author":"S Parvin","year":"2019","unstructured":"Parvin S, Ramirez-Labrada A, Aumann S et al (2019) LMO2 confers synthetic lethality to PARP inhibition in DLBCL. Cancer Cell 36:237\u2013249.e236","journal-title":"Cancer Cell"},{"key":"5359_CR10","doi-asserted-by":"publisher","first-page":"5588","DOI":"10.1158\/0008-5472.CAN-12-2753","volume":"72","author":"J Murai","year":"2012","unstructured":"Murai J, Huang SY, Das BB et al (2012) Trapping of PARP1 and PARP2 by clinical PARP inhibitors. Cancer Res 72:5588\u20135599","journal-title":"Cancer Res"},{"key":"5359_CR11","doi-asserted-by":"publisher","first-page":"742","DOI":"10.1016\/j.molcel.2015.10.032","volume":"60","author":"S Eustermann","year":"2015","unstructured":"Eustermann S, Wu WF, Langelier MF et al (2015) Structural basis of detection and signaling of DNA single-strand breaks by human PARP-1. Mol Cell 60:742\u2013754","journal-title":"Mol Cell"},{"key":"5359_CR12","doi-asserted-by":"publisher","first-page":"520","DOI":"10.1016\/j.celrep.2016.12.042","volume":"18","author":"M Isono","year":"2017","unstructured":"Isono M, Niimi A, Oike T et al (2017) BRCA1 Directs the repair pathway to homologous recombination by promoting 53BP1 dephosphorylation. Cell Rep 18:520\u2013532","journal-title":"Cell Rep"},{"key":"5359_CR13","doi-asserted-by":"publisher","first-page":"5564","DOI":"10.1073\/pnas.1216824110","volume":"110","author":"EM Kass","year":"2013","unstructured":"Kass EM, Helgadottir HR, Chen CC et al (2013) Double-strand break repair by homologous recombination in primary mouse somatic cells requires BRCA1 but not the ATM kinase. Proc Natl Acad Sci U S A 110:5564\u20135569","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5359_CR14","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.tcb.2015.07.009","volume":"26","author":"R Ceccaldi","year":"2016","unstructured":"Ceccaldi R, Rondinelli B, D'Andrea AD (2016) Repair pathway choices and consequences at the double-strand break. Trends Cell Biol 26:52\u201364","journal-title":"Trends Cell Biol"},{"key":"5359_CR15","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1016\/j.radonc.2017.10.017","volume":"126","author":"R de Haan","year":"2018","unstructured":"de Haan R, Pluim D, van Triest B et al (2018) Improved pharmacodynamic (PD) assessment of low dose PARP inhibitor PD activity for radiotherapy and chemotherapy combination trials. Radiother Oncol 126:443\u2013449","journal-title":"Radiother Oncol"},{"key":"5359_CR16","doi-asserted-by":"publisher","first-page":"2972","DOI":"10.1016\/j.ejca.2013.05.020","volume":"49","author":"JF Liu","year":"2013","unstructured":"Liu JF, Tolaney SM, Birrer M et al (2013) A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer. Eur J Cancer 49:2972\u20132978","journal-title":"Eur J Cancer"},{"key":"5359_CR17","doi-asserted-by":"publisher","first-page":"43978","DOI":"10.18632\/oncotarget.6287","volume":"6","author":"A Herriott","year":"2015","unstructured":"Herriott A, Tudhope SJ, Junge G et al (2015) PARP1 expression, activity and ex vivo sensitivity to the PARP inhibitor, talazoparib (BMN 673), in chronic lymphocytic leukaemia. Oncotarget 6:43978\u201343991","journal-title":"Oncotarget"},{"key":"5359_CR18","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1038\/nrd2133","volume":"5","author":"JE Bolden","year":"2006","unstructured":"Bolden JE, Peart MJ, Johnstone RW (2006) Anticancer activities of histone deacetylase inhibitors. Nat Rev Drug Discov 5:769\u2013784","journal-title":"Nat Rev Drug Discov"},{"key":"5359_CR19","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1080\/13543776.2017.1276565","volume":"27","author":"HT Qin","year":"2017","unstructured":"Qin HT, Li HQ, Liu F (2017) Selective histone deacetylase small molecule inhibitors: recent progress and perspectives. Expert Opin Ther Pat 27:621\u2013636","journal-title":"Expert Opin Ther Pat"},{"key":"5359_CR20","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1093\/annonc\/mdv237","volume":"26","author":"Y Shi","year":"2015","unstructured":"Shi Y, Dong M, Hong X et al (2015) Results from a multicenter, open-label, pivotal phase II study of chidamide in relapsed or refractory peripheral T-cell lymphoma. Ann Oncol 26:1766\u20131771","journal-title":"Ann Oncol"},{"key":"5359_CR21","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1186\/s13045-017-0439-6","volume":"10","author":"Y Shi","year":"2017","unstructured":"Shi Y, Jia B, Xu W et al (2017) Chidamide in relapsed or refractory peripheral T cell lymphoma: a multicenter real-world study in China. J Hematol Oncol 10:69","journal-title":"J Hematol Oncol"},{"key":"5359_CR22","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1186\/s13046-018-0810-7","volume":"37","author":"L Yin","year":"2018","unstructured":"Yin L, Liu Y, Peng Y et al (2018) PARP inhibitor veliparib and HDAC inhibitor SAHA synergistically co-target the UHRF1\/BRCA1 DNA damage repair complex in prostate cancer cells. J Exp Clin Cancer Res 37:153","journal-title":"J Exp Clin Cancer Res"},{"key":"5359_CR23","doi-asserted-by":"publisher","first-page":"e11208","DOI":"10.1371\/journal.pone.0011208","volume":"5","author":"SK Kachhap","year":"2010","unstructured":"Kachhap SK, Rosmus N, Collis SJ et al (2010) Downregulation of homologous recombination DNA repair genes by HDAC inhibition in prostate cancer is mediated through the E2F1 transcription factor. PLoS One. 5:e11208","journal-title":"PLoS One."},{"key":"5359_CR24","doi-asserted-by":"publisher","first-page":"4788","DOI":"10.1182\/bloodadvances.2020002049","volume":"4","author":"O Kruglov","year":"2020","unstructured":"Kruglov O, Wu X, Hwang ST, Akilov OE (2020) The synergistic proapoptotic effect of PARP-1 and HDAC inhibition in cutaneous T-cell lymphoma is mediated via Blimp-1. Blood Adv 4:4788\u20134797","journal-title":"Blood Adv"},{"key":"5359_CR25","doi-asserted-by":"publisher","first-page":"101084","DOI":"10.1016\/j.redox.2018.101084","volume":"25","author":"US Srinivas","year":"2019","unstructured":"Srinivas US, Tan BWQ, Vellayappan BA, Jeyasekharan AD (2019) ROS and the DNA damage response in cancer. Redox Biol 25:101084","journal-title":"Redox Biol"},{"key":"5359_CR26","doi-asserted-by":"publisher","first-page":"4839","DOI":"10.7150\/thno.56747","volume":"11","author":"Y Wang","year":"2021","unstructured":"Wang Y, Qi H, Liu Y et al (2021) The double-edged roles of ROS in cancer prevention and therapy. Theranostics 11:4839\u20134857","journal-title":"Theranostics"},{"key":"5359_CR27","doi-asserted-by":"publisher","first-page":"102065","DOI":"10.1016\/j.ctrv.2020.102065","volume":"89","author":"L Wang","year":"2020","unstructured":"Wang L, Li LR, Zhang L, Wang JW (2020) The landscape of new drugs in extranodal NK\/T-cell lymphoma. Cancer Treat Rev 89:102065","journal-title":"Cancer Treat Rev"},{"issue":"Suppl 1","key":"5359_CR28","doi-asserted-by":"publisher","first-page":"i1","DOI":"10.1093\/annonc\/mdw082","volume":"27","author":"SB Kaye","year":"2016","unstructured":"Kaye SB (2016) Progress in the treatment of ovarian cancer-lessons from homologous recombination deficiency-the first 10 years. Ann Oncol 27(Suppl 1):i1\u2013i3","journal-title":"Ann Oncol"},{"key":"5359_CR29","doi-asserted-by":"publisher","first-page":"1114","DOI":"10.1038\/bjc.2011.382","volume":"105","author":"M Javle","year":"2011","unstructured":"Javle M, Curtin NJ (2011) The role of PARP in DNA repair and its therapeutic exploitation. Br J Cancer 105:1114\u20131122","journal-title":"Br J Cancer"},{"key":"5359_CR30","doi-asserted-by":"publisher","first-page":"590","DOI":"10.1002\/ijc.34027","volume":"151","author":"U Khalid","year":"2022","unstructured":"Khalid U, Simovic M, Hammann LA et al (2022) A synergistic interaction between HDAC- and PARP inhibitors in childhood tumors with chromothripsis. Int J Cancer 151:590\u2013606","journal-title":"Int J Cancer"},{"key":"5359_CR31","doi-asserted-by":"publisher","first-page":"13650","DOI":"10.1073\/pnas.1203326109","volume":"109","author":"SR Stecklein","year":"2012","unstructured":"Stecklein SR, Kumaraswamy E, Behbod F et al (2012) BRCA1 and HSP90 cooperate in homologous and non-homologous DNA double-strand-break repair and G2\/M checkpoint activation. Proc Natl Acad Sci U S A 109:13650\u201313655","journal-title":"Proc Natl Acad Sci U S A"},{"key":"5359_CR32","doi-asserted-by":"publisher","first-page":"1064","DOI":"10.1111\/cas.13947","volume":"110","author":"L Wang","year":"2019","unstructured":"Wang L, Yang C, Xie C et al (2019) Pharmacologic characterization of fluzoparib, a novel poly(ADP-ribose) polymerase inhibitor undergoing clinical trials. Cancer Sci 110:1064\u20131075","journal-title":"Cancer Sci"},{"key":"5359_CR33","doi-asserted-by":"publisher","first-page":"2479","DOI":"10.1158\/1078-0432.CCR-08-1931","volume":"15","author":"AI Daud","year":"2009","unstructured":"Daud AI, Dawson J, DeConti RC et al (2009) Potentiation of a topoisomerase I inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase I\/II clinical trial. Clin Cancer Res 15:2479\u20132487","journal-title":"Clin Cancer Res"},{"key":"5359_CR34","doi-asserted-by":"publisher","first-page":"2732","DOI":"10.1182\/blood-2009-11-256354","volume":"116","author":"Y Hu","year":"2010","unstructured":"Hu Y, Lu W, Chen G et al (2010) Overcoming resistance to histone deacetylase inhibitors in human leukemia with the redox modulating compound \u03b2-phenylethyl isothiocyanate. Blood 116:2732\u20132741","journal-title":"Blood"},{"key":"5359_CR35","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.ccell.2020.02.005","volume":"37","author":"J Xiong","year":"2020","unstructured":"Xiong J, Cui BW, Wang N et al (2020) Genomic and transcriptomic characterization of natural killer T cell lymphoma. Cancer Cell 37:403\u2013419.e406","journal-title":"Cancer Cell"},{"key":"5359_CR36","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/ng837","volume":"30","author":"RI Yarden","year":"2002","unstructured":"Yarden RI, Pardo-Reoyo S, Sgagias M, Cowan KH, Brody LC (2002) BRCA1 regulates the G2\/M checkpoint by activating Chk1 kinase upon DNA damage. Nat Genet 30:285\u2013289","journal-title":"Nat Genet"},{"key":"5359_CR37","doi-asserted-by":"publisher","first-page":"e1526","DOI":"10.1002\/onco.13829","volume":"26","author":"M Toh","year":"2021","unstructured":"Toh M, Ngeow J (2021) Homologous recombination deficiency: cancer predispositions and treatment implications. Oncologist 26:e1526\u2013e1537","journal-title":"Oncologist"},{"key":"5359_CR38","doi-asserted-by":"publisher","first-page":"107492","DOI":"10.1016\/j.pharmthera.2020.107492","volume":"208","author":"E Laurini","year":"2020","unstructured":"Laurini E, Marson D, Fermeglia A, Aulic S, Fermeglia M, Pricl S (2020) Role of Rad51 and DNA repair in cancer: a molecular perspective. Pharmacol Ther 208:107492","journal-title":"Pharmacol Ther"},{"key":"5359_CR39","doi-asserted-by":"publisher","first-page":"118669","DOI":"10.1016\/j.saa.2020.118669","volume":"241","author":"Y Xie","year":"2020","unstructured":"Xie Y, Tang P, Xing X et al (2020) In situ exploring Chidamide, a histone deacetylase inhibitor, induces molecular changes of leukemic T-lymphocyte apoptosis using Raman spectroscopy. Spectrochim Acta A Mol Biomol Spectrosc 241:118669","journal-title":"Spectrochim Acta A Mol Biomol Spectrosc"},{"key":"5359_CR40","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/nrc2628","volume":"9","author":"F Balkwill","year":"2009","unstructured":"Balkwill F (2009) Tumour necrosis factor and cancer. Nat Rev Cancer 9:361\u2013371","journal-title":"Nat Rev Cancer"},{"key":"5359_CR41","doi-asserted-by":"publisher","first-page":"2185","DOI":"10.1016\/j.ymthe.2021.03.022","volume":"29","author":"H Wang","year":"2021","unstructured":"Wang H, Cheng Y, Mao C et al (2021) Emerging mechanisms and targeted therapy of ferroptosis in cancer. Mol Ther 29:2185\u20132208","journal-title":"Mol Ther"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05359-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05359-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05359-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,9]],"date-time":"2023-09-09T11:04:04Z","timestamp":1694257444000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05359-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,7,27]]},"references-count":41,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["5359"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05359-3","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,7,27]]},"assertion":[{"value":"19 March 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The animal protocol was approved by the Institutional Animal Care and Use Committee of the First Affiliated Hospital of Zhengzhou University and complied with the National Institutes of Health Guide for the Care and Use of Laboratory Animals.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}